George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Group Regulatory News (SAG)

Share Price Information for Science Group (SAG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 415.00
Bid: 410.00
Ask: 420.00
Change: 0.00 (0.00%)
Spread: 10.00 (2.439%)
Open: 415.00
High: 415.00
Low: 415.00
Prev. Close: 415.00
SAG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Audited results for year ended 31 December 2023

21 Mar 2024 07:00

RNS Number : 6886H
Science Group PLC
21 March 2024
 

 

 

21 March 2024

SCIENCE GROUP PLC

 

AUDITED RESULTS

FOR THE YEAR ENDED 31 DECEMBER 2023

 

Science Group plc (the 'Company') together with its subsidiaries ('Science Group' or the 'Group') reports its audited results for the year ended 31 December 2023.

 

· Group revenue increased to £113.3 million (2022: £86.3 million), including contribution from TP Group acquired in January 2023

· Adjusted* operating profit increased to £20.5 million (2022: £17.6 million)

· Adjusted* basic earnings per share increased to 33.3 pence (2022: 29.4 pence)

· Dividend proposed to increase by 60% to 8.0 pence (2022: 5.0 pence), reflecting the significant increase in scale of the Group in recent years

· Share buy-back of £3.9 million in 2023 at an average price of 403 pence (2022: £1.3 million at average 408 pence). Programme anticipated to continue in 2024

· Year-end cash of £30.9 million with net funds of £18.0 million (2022: £43.6 million and £29.5 million, respectively) after completion of the TP Group acquisition and share buy-back. Additional undrawn credit facility of £25.0 million

 

 

 

Science Group plc

Martyn Ratcliffe, Executive Chair

Jon Brett, Finance Director

Tel: +44 (0) 1223 875 200

www.sciencegroup.com

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)

Nick Adams, Fred Walsh, Richard Short

 

Tel: +44 (0) 20 7710 7600

Liberum Capital Limited (Joint Broker)

Max Jones, Miquela Bezuidenhoudt

Tel: +44 (0) 20 3100 2000

* Alternative performance measures are provided in order to reflect the underlying financial performance of the Group. Refer to Note 1 for detail and explanation of the measures used.

 

Statement of Executive Chair

Science Group plc is an international science & technology consultancy and systems organisation. The Group's operating businesses are supported by a scalable corporate and shared services infrastructure and underpinned by a robust balance sheet including significant cash resources and freehold property assets.

Since 2010, the Group has established a strong operating track record, enhanced by a successful M&A strategy, delivering consistent performance through economic volatility, the pandemic and geo-political instability. In 2023, Science Group again demonstrated the effectiveness of its operating model in a challenging macro-environment and, whilst not immune to market dynamics, the Group has reported record underlying operating results.

Financial Summary

For the year ended 31 December 2023, Science Group reported revenue of £113.3 million (2022: £86.3 million). Adjusted operating profit increased to £20.5 million (2022: £17.6 million) and adjusted basic earnings per share increased to 33.3 pence (2022: 29.4 pence). Consistent with the Board's emphasis on cash flow, the Group does not capitalise R&D costs although certain investments, of between £1.0 million and £1.5 million, could have been considered appropriate for capitalisation.

Adjusting items, which are primarily non-cash, are detailed in the Finance Director's report and include one-off items related to the TP Group ('TPG') acquisition (completed in January 2023). Accordingly, the Group's reported statutory operating profit was £8.1 million for the year (2022: £11.7 million) and profit before tax was £7.6 million (2022: £11.1 million). The Group also incurred a higher tax charge, impacting statutory post-tax profit and basic earnings per share.

Science Group retains an asset-rich balance sheet, including significant cash resources and freehold property. Despite completing the Group's largest acquisition in January 2023 (cash outflow in the year of approximately £13.9 million) and a substantial share buy-back programme (cash outflow of £3.9 million), at 31 December 2023 Group cash was £30.9 million (2022: £43.6 million) and net funds were £18.0 million (2022: £29.5 million). The Group's term loan, which expires in 2026, was £13.0 million (2022: £14.1 million) in addition to which the Group has an undrawn £25 million Revolving Credit Facility ('RCF') which has been extended to December 2026.

Consultancy Services

The nucleus of Science Group is an international science and technology consultancy, providing technical/scientific advisory, product development and regulatory services to the Industrial, Defence & Aerospace, Medical and Consumer (including Food & Beverage) sectors. The deep technical and scientific expertise combined with specialist industry knowledge defines the strategy of Science Group's Consultancy operations.

The Consultancy Division comprises distinct practices, characterised by capability, geography or industry sector. Whilst operating autonomously, these practices have tangible synergies and collaboration is actively developed, supported by common incentive programmes, to realise the benefits of scale. For example, a substantial proportion of projects in 2023 addressed sustainability objectives of Science Group clients achieved through multi-disciplinary teams.

The completion of the acquisition of TPG in January 2023 expanded the Group's addressable market with the addition of Defence and Aerospace focused consultancy services ('TPGS'), while also opening up new opportunities for the Group's existing capabilities. Like most market sectors, Defence and Aerospace has high barriers to entry, requiring an understanding of the market characteristics, processes and dynamics.

For the year ended 31 December 2023, the Consultancy Services operations generated revenue of £81.3 million (2022: £60.7 million), including eleven months of TPGS producing an adjusted operating profit increase to £20.4 million (2022: £16.2 million). The established operations within the Division deliver consistently high margins, reflecting the market positioning of Science Group and an efficient operating model, but the margin overall in 2023 reduced due to the currently lower profitability of TPGS.

While the TPGS integration increased the proportion of Consultancy revenue derived from the UK, the Consultancy Division remains internationally diversified with around 30% of revenues invoiced in US dollars in addition to other currencies. Given the proportion of revenue invoiced in US dollars, against a primarily Sterling cost base, the Board initiated a currency hedging option for a proportion of the Consultancy cash flows in 2023 and a similar instrument has been adopted for 2024.

Systems Businesses

The Group has two systems businesses, both of which have leading positions in their niche markets. These 'satellites' operate independently but are supported by the Group's corporate and shared services infrastructure and have access to the Consultancy Division's science, technology and engineering expertise providing R&D breadth and depth far beyond what would typically be available to operations of their scale. In aggregate, for the year ended 31 December 2023, the Systems businesses reported revenue of £31.2 million (2022: £25.0 million) and an adjusted operating profit of £2.2 million (2022: £3.9 million).

Submarine Atmosphere Management Systems (CMS2) was part of TP Group and required considerable attention following Science Group's initial investment in 2021. This focus has continued after the acquisition was completed in 2023, including strengthening management, improving operational/commercial process/governance and R&D support. While servicing an international client base, the systems are of a highly bespoke nature and the business remains dependent on the UK defence market. For the eleven months ended 31 December 2023, CMS2 reported revenue of £21.3 million (2022: £nil) of which added-value and services contribute around 60%. The adjusted operating margin in 2023 was higher than anticipated, benefitting from some one-off effects.

Audio Chips and Modules (Frontier) is the global market leader in DAB/DAB+/Smart Radio chips and modules and is developing new-technology connected audio products. In line with the broader consumer electronics market, the economic downturn, compounded by overstocking in the distribution channel related to the post-Covid supply chain imbalances, impacted the Frontier business in 2023. As a result, revenue reduced to £10.0 million (2022: £25.0 million) with a small operating loss, although this included significant investment in new product development, all of which was expensed in the year with no capitalisation of R&D. Despite the challenging market conditions, Frontier is believed to have retained its substantial market share and premium positioning and the Board anticipates the business will see a recovery in 2024, benefitting from wider market/economic dynamics and the operational cost reduction actions undertaken during the past year.

Corporate

The corporate function is responsible for the strategic development and governance of Science Group. The underlying costs of the corporate function were static at £2.6 million (2022: £2.6 million). Total corporate costs additionally include one-off items associated with acquisitions and therefore are reported as £8.1 million (2022: £3.2 million). These primarily non-cash adjusting items are detailed in the Finance Director's report.

During the year, the Company repurchased 961,385 shares at a total cost of £3.9 million (2022: £1.3 million), equivalent to an average price of 403 pence per share. At 31 December 2023, shares in issue (excluding treasury shares held of 0.7 million) were 45.5 million (2022: 45.4 million excluding treasury shares held of 0.7 million). The Board anticipates continuing the buy-back programme in 2024, as appropriate.

Reflecting the significant increase in the scale of Science Group in recent years, together with the track record of performance, the Board is recommending increasing the dividend by 60% to 8.0 pence per share (2022: 5.0 pence per share). Subject to shareholder approval at the Annual General Meeting ('AGM'), the dividend will be payable on 19 July 2024 to shareholders on the register at the close of business on 21 June 2024.

Science Group owns two freehold properties, Harston Mill, near Cambridge, and Great Burgh, near Epsom, the primary function of which is to host the Group's operating businesses. The Group charges market rents to the operating businesses and lets out part of the Harston Mill site to third parties. For the year ended 31 December 2023, the rental and associated services income derived from this activity was £4.2 million (2022: £4.1 million), of which around 20% is generated from third party tenants. Intra-group rental charges are eliminated on Group consolidation. The last independent valuation of the freehold properties (December 2023) indicated an aggregate value in the range of £16.9 million to £31.6 million, although for consistency the properties are held on the balance sheet on a cost basis of £20.6 million (2022: £20.8 million).

Environmental Reporting

In 2023 the Group undertook Streamlined Energy and Carbon Reporting (SECR) for the first time and is reporting Scope 1, 2 and mandatory Scope 3 emissions from its UK operations. The Group is also disclosing climate-related risk in line with the Task Force on Climate-Related Financial Disclosures (TCFD) framework. For the latter initiative, the Group worked with a specialist third-party consultancy, and concluded that the Group's exposure to climate-related risk is low.

Summary and Outlook

In summary, Science Group has delivered another solid performance in 2023. This resilience has been achieved against the backdrop of significant geopolitical and economic instability which the Board anticipates will persist through the first half of 2024.

The acquisition of TP Group materially increased the scale and expanded the addressable market of Science Group. The contribution made by the TP Group businesses in 2023 indicates that the acquisition remains on trajectory to meet the Group's acquisition objectives.

For over a decade, Science Group has demonstrated a consistent operating track record, enhanced by a successful M&A programme, delivering a substantial return for shareholders. While the Group has the ambition and capability to accelerate the strategy, the relative valuation of the company against both UK and international comparators may prove a material constraint. The Board will therefore consider all options to address this disparity and deliver value to shareholders.

 

 

Martyn Ratcliffe

Executive Chair

 

 

 

Finance Director's Report

Overview of Results

 

In the year ended 31 December 2023, the Group generated revenue of £113.3 million (2022: £86.3 million). Revenue from the Consultancy Services Segment, that is revenue derived from consultancy services and materials recharged on projects, increased to £81.3 million (2022: £60.7 million) while Systems revenue generated by the CMS2 Business was £21.3 million (2022: £nil) and Systems revenue generated by the Frontier Business was £10.0 million (2022: £25.0 million). Revenue generated by freehold properties, comprising property and associated services income derived from space let to third parties in the Harston Mill facility, was £0.8 million (2022: £0.7 million).

 

Adjusted operating profit for the Group increased to £20.5 million (2022: £17.6 million). There were one-off adjusting items related to the TP Group plc ('TPG') acquisition, which completed on 26 January 2023, totalling £5.5 million (2022: £0.5 million). The majority of these were non-cash and included items such as: share of loss for the period held as an associate; remeasurement of share valuation at point of acquisition (in accordance with IFRS 3 Business Combinations); professional fees; and integration/restructuring. In addition, and driven by the acquisition of TPG, amortisation of acquisition-related intangible assets increased to £4.9 million (2022: £3.8 million). Share-based payment charges for the year totalled £2.0 million (2022: £1.6 million), which resulted in statutory profit before tax of £7.6 million (2022: £11.1 million). After net finance costs of £0.5 million (2022: £0.6 million) and a tax charge of £2.1 million (2022: £0.5 million), statutory profit after tax was £5.5 million (2022: £10.6 million). Statutory basic earnings per share was 12.1 pence (2022: 23.2 pence per share).

 

Adjusted operating profit is an alternative profit measure that is calculated as operating profit excluding acquisition integration costs, amortisation of acquisition related intangible assets, share based payment charges, and other specified items that meet the criteria to be adjusted. Refer to the notes to the financial statements for further information on this and other alternative performance measures.

 

TP Group plc ('TPG')

 

Prior to 2023, through on-market purchases of shares, the Group had acquired an associate shareholding in TPG. A full acquisition was completed through a court-approved Scheme of Arrangement on 26 January 2023, at which point TPG became a 100% subsidiary of the Group. 

As well as providing an entry into the defence sector, the acquisition of TPG has significantly increased the scale of Science Group. In 2023, the TPG trading entities contributed £44.9 million towards Group revenue.

 

Foreign Exchange

 

The acquisition of TPG, where revenue is denominated in Sterling, has reduced the Group's overall exposure to foreign exchange, however, there remains a reasonable proportion of the Group's revenue denominated in currencies other than Sterling. In 2023, £34.6 million of the Group's operating business revenue was denominated in US Dollars (2022: £54.7 million), including all of Frontier's revenue. In addition, £3.9 million of the Group operating business revenue was denominated in Euros (2022: £2.7 million). The average exchange rates during 2023 were 1.24 for US Dollars and 1.15 for Euros (2022: 1.24 and 1.18 respectively).

In 2022, to provide greater forward visibility around foreign exchange, the Group acquired a currency exchange instrument to cap the Sterling:US Dollar rate in relation to certain consultancy cash flows through to the end of 2023. The instrument applied to $1.25 million per month at an exchange rate of $1.20/£1, whilst still allowing the business to benefit from lower spot exchange rates if available. A similar no obligation cap has been put in place through 2024 for $1.0 million per month at an exchange rate of $1.25/£1.

 

Taxation

 

The tax charge for the year was £2.1 million (2022: £0.5 million). The increase is partly explained by tax at a higher rate, with the UK corporation tax rate increasing from 19% to 25% in April 2023. However, as a comparative, the 2022 tax charge was exceptionally low due to deferred tax and some over accrual in 2021.

At 31 December 2023, Science Group had £29.3 million (2022: £26.7 million) of tax losses, the largest components of which related to Frontier (£19.2 million (2022: £17.1 million)) and TPG (£5.9 million (2022: £nil)). £9.1 million (2022: £8.7 million) of the Frontier losses, and £5.4 million (2022: £nil) of the TPG losses are recognised as deferred tax assets which are anticipated to be used to offset future taxable profits. The balances of £10.1 million (2022: £8.4 million) of the Frontier losses and £0.5 million (2022: £nil) of the TPG losses have not been recognised as deferred tax assets due to the uncertainty in the timing of utilisation of these losses. Aside from these amounts, the Group has other tax losses of £4.2 million (2022: £9.6 million) unrecognised as a deferred tax asset due to the low probability that these losses will be utilised.

 

Financing and Cash

 

Cash flow from operating activities (excluding Client Registration Funds) was £8.9 million (2022: £15.3 million). Reported cash from operating activities in accordance with IFRS was £7.9 million (2022: £15.3 million). The difference in these two metrics relates to the fact that one of the Group's businesses, TSG, processes regulatory registration payments on behalf of clients. The alternative performance measure, by excluding Client Registration Funds, reflects the Group's available cash position and cash flow.

 

The Group's term loan with Lloyds Bank plc, secured on the Group's freehold properties, is a 10-year fixed term loan expiring in 2026. Phased interest rate swaps hedge the loan resulting in a fixed effective interest rate of 3.5%, comprising: a margin over the Sterling Overnight Index Average ('SONIA'); the cost of the loan arrangement fee; and, the cost of the swap instruments. The Group has adopted hedge accounting for the interest rate swaps related to the bank loan under IFRS 9, Financial Instruments, and the change in fair value of the interest rate swaps was recognised in Other Comprehensive Income (2023: a loss of £0.5 million, 2022: a gain of £1.3 million).

In December 2021, in addition to the term loan, the Group signed a £25.0 million revolving credit facility ('RCF') with Lloyds Bank plc in order to provide additional capital resources to enable the execution of the Group's acquisition strategy. The RCF is for up to £25.0 million, with an additional £5.0 million accordion option. The agreement was initially for a 4-year term with an optional 1-year extension which was activated in December 2023, so the term now runs to December 2026. The margin on drawn sums is 3.3% over SONIA and is 1.1% per annum on undrawn amounts. Drawn amounts are secured on the Group's assets by debentures. At 31 December 2023, the RCF remained undrawn.

The RCF has two financial covenants with which the Group needs to comply if the facility is drawn: (i) the Group's net leverage, as defined as the net debt divided by the rolling 12 month EBITDA, should not exceed 2.5; and (ii) the Group's interest cover, as defined as the rolling 12 month EBITDA divided by the rolling interest payments on all borrowings, should not be less than 4.0. Reporting is on a 6 monthly basis unless the net leverage exceeds 2, in which case reporting moves to quarterly until net leverage returns to below 2 again. For the term of the RCF, the previous covenants for the term loan are superseded by the covenants of the RCF and will not apply.

The Group cash balance (excluding Client Registration Funds) at 31 December 2023 was £30.9 million (2022: £43.6 million) and net funds were £18.0 million (2022: £29.5 million). Client Registration Funds of £1.9 million (2022: £2.9 million) were held at the year end. Working capital was partly impacted by the TPG acquisition, together with some one-off project prepayments received at the end of 2022, which have since normalised. Working capital management during the year continued to be a focus with debtor days of 40 days at 31 December 2023 (2022: 43 days) and inventory days of 121 days (2022: 197 days).

 

Share Capital

 

At 31 December 2023, the Company had 45,458,972 ordinary shares in issue (2022: 45,436,823) and the Company held an additional 726,902 shares in treasury (2022: 749,051). Of the ordinary shares in issue, no shares are held by the Frontier Employee Benefit Trust (2022: 34,800). The voting rights in the Company at 31 December 2023 are 45,458,972 (2022: 45,402,023). In this report, all references to measures relative to the number of shares in issue exclude shares held in treasury unless explicitly stated to the contrary.

 

 

Jon Brett

Finance Director

Consolidated Income Statement

For the year ended 31 December 2023

 

Note

2023

£000

2022

£000

Revenue

2

113,341

86,301

Direct operating expenses

(67,090)

(47,947)

Sales and marketing expenses

(9,206)

(9,754)

Administrative expenses

(28,731)

(17,504)

Share of (loss)/profit of equity accounted investment

(169)

602

 

Adjusted operating profit

2

20,535

17,602

Acquisition integration costs

(518)

(1,128)

Amortisation of acquisition related intangible assets

7

(4,944)

(3,766)

Loss on remeasurement of equity-accounted investment

(4,762)

-

Share-based payment charge

(1,997)

(1,612)

Share of (loss)/profit of equity-accounted investment

(169)

602

Operating profit

8,145

11,698

Finance income

679

375

Finance costs

(1,205)

(977)

Profit before tax

7,619

11,096

Tax charge (net of R&D tax credit of £517,000(2022: £530,000))

 

3

 

(2,095)

 

(541)

Profit for the year

5,524

10,555

Earnings per share

 

Earnings per share (basic)

5

12.1p

23.2p

Earnings per share (diluted)

5

12.0p

22.6p

 

 

Consolidated Statement of Comprehensive Income

For the year ended 31 December 2023

 

 

2023£000

2022£000

Profit for the year attributable to:

 

 

Equity holders of the parent

 

5,524

10,555

Profit for the year

 

5,524

10,555

Other comprehensive income items

that will or may be reclassified to profit or loss:

 

 

Exchange differences on translating foreign operations

 

(848)

2,372

Fair value (loss)/gain on financial instruments

(441)

1,499

Deferred tax credit/(charge) on financial instruments

147

(414)

Other comprehensive (expense)/income for the year

 

(1,142)

3,457

Total comprehensive income for the period attributable to:

 

 

Equity holders of the parent

 

4,382

14,012

Total comprehensive income for the year

 

4,382

14,012

 

 

Consolidated Statement of Changes in Shareholders' Equity

For the year ended 31 December 2023

 

 

 

Share capital

£000

Share premium

 

£000

Treasury shares

 

£000

Merger reserve

£000

Translation reserve

£000

Cashflow hedge reserve

£000

Retained earnings

£000

Total equity

 

£000

Balance at 1 January 2022

462

26,834

(1,242)

10,343

(758)

74

30,579

66,292

Contributions and distributions:

Purchase of own shares

-

-

(1,321)

-

-

-

-

(1,321)

Issue of shares out of treasury

-

-

370

-

-

-

(369)

1

Dividends paid (Note 6)

-

-

-

-

-

-

(2,270)

(2,270)

Share-based payment charge

-

-

-

-

-

-

1,612

1,612

Deferred tax charge on share-based payment transactions

-

-

-

-

-

-

(127)

(127)

Transactions with owners

-

-

(951)

-

-

-

(1,154)

(2,105)

Profit for the year

-

-

-

-

-

-

10,555

10,555

Other comprehensive income items that

will or maybe reclassed to profit or loss:

Fair value gain on financial instruments

-

-

-

-

-

1,499

-

1,499

Exchange differences on translating foreign operations

-

-

-

-

2,372

-

-

2,372

Deferred tax charge on financial instruments

-

-

-

-

-

(414)

-

(414)

Total comprehensive income for the year

-

-

-

-

2,372

1,085

10,555

14,012

Balance at 31 December 2022

462

26,834

(2,193)

10,343

1,614

1,159

39,980

78,199

 

 

Consolidated Statement of Changes in Shareholders' Equity

For the year ended 31 December 2023

 

 

Share capital

£000

Share premium

 

£000

Treasury shares

 

£000

Merger reserve

£000

Translation reserve

£000

Cashflow hedge reserve

£000

Retained earnings

£000

Total equity

 

£000

Balance at 1 January 2023

462

26,834

(2,193)

10,343

1,614

1,159

39,980

78,199

Contributions and distributions:

Purchase of own shares

-

-

(3,875)

-

-

-

-

(3,875)

Issue of shares out of treasury

-

-

3,138

-

-

-

(3,128)

10

Dividends paid (Note 6)

-

-

-

-

-

-

(2,259)

(2,259)

Share-based payment charge

-

-

-

-

-

-

1,997

1,997

Deferred tax charge on share-based payment transactions

-

-

-

-

-

-

(467)

(467)

Transactions with owners

-

-

(737)

-

-

-

(3,857)

(4,594)

Profit for the year

-

-

-

-

-

-

5,524

5,524

Other comprehensive income items that

will or maybe reclassed to profit or loss:

 

Fair value loss on financial instruments

-

-

-

-

-

(441)

-

(441)

Exchange differences on translating foreign operations

-

-

-

-

(848)

-

-

(848)

Deferred tax charge on financial instruments

-

-

-

-

-

147

-

147

Total comprehensive income for the year

-

-

-

-

(848)

(294)

5,524

4,382

Balance at 31 December 2023

462

26,834

(2,930)

10,343

766

865

41,647

77,987

 

Consolidated Balance Sheet

At 31 December 2023

 

Note

2023

£000

2022

£000

Assets

 

Non-current assets

 

Acquisition related intangible assets

7

25,845

10,815

Goodwill

7

18,878

14,975

Property, plant and equipment

 

25,477

23,867

Investments

 

-

10,054

Derivative financial instruments

886

1,417

Deferred tax assets

4

2,071

2,176

73,157

63,304

Current assets

 

Inventories

8

1,332

2,477

Trade and other receivables

9

23,315

12,992

Current tax assets

1,516

1,607

Derivative financial instruments

301

384

Cash and cash equivalents - Group cash

10

30,949

43,645

Cash and cash equivalents - Client registration funds

10

1,881

2,867

59,294

63,972

Total assets

132,451

127,276

Liabilities

 

Current liabilities

 

Trade and other payables

11

32,041

31,546

Current tax liabilities

379

331

Provisions

12

1,481

849

Borrowings

14

1,200

1,200

Lease liabilities

626

720

35,727

34,646

Non-current liabilities

 

Provisions

12

889

248

Borrowings

14

11,756

12,939

Lease liabilities

3,319

1,162

Deferred tax liabilities

4

2,773

82

18,737

14,431

Total liabilities

54,464

49,077

Net assets

77,987

78,199

Shareholders' equity

 

Share capital

13

462

462

Share premium

26,834

26,834

Treasury shares

(2,930)

(2,193)

Merger reserve

10,343

10,343

Translation reserve

766

1,614

Cash flow hedge reserve

865

1,159

Retained earnings

41,647

39,980

Total equity

77,987

78,199

 

 

Consolidated Statement of Cash Flows

For the year ended 31 December 2023

 

Note

2023

£000

2022

£000

Profit before income tax

7,619

11,096

Adjustments for:

 

Share of loss/(profit) of equity accounted investment

169

(602)

Loss on remeasurement of equity-accounted investee

4,762

-

Amortisation of acquisition related intangible assets

7

4,944

3,766

Depreciation of property, plant and equipment

694

655

Reversal of impairment of right-of-use assets

-

(215)

Depreciation of right-of-use assets

1,053

827

Bank charges on derivative financial instruments

422

359

Net interest cost

526

602

Share-based payment charge

1,997

1,612

Decrease/(increase) in inventories

1,222

(23)

(Increase)/decrease in receivables

(2,019)

(680)

Decrease in payables representing client registration funds

(986)

(7)

(Decrease)/increase in payables excluding balances representing client registration funds*

(10,760)

1,235

Increase/(decrease) in provisions

662

(263)

Cash generated from operations

10,305

18,362

Interest paid

(1,106)

(808)

UK corporation tax paid

(962)

(1,017)

Foreign corporation tax paid

(325)

(1,266)

Cash flows from operating activities

7,912

15,271

Interest received

583

271

Purchase of property, plant and equipment

(80)

(92)

Purchase of interest in associated company

-

(213)

Purchase of subsidiary undertakings, net of cash and borrowing acquired

 

15

(13,923)

-

Sale of subsidiary, net of cash sold

638

-

Cash flows used in investing activities

(12,782)

(34)

Issue of shares out of treasury

10

1

Repurchase of own shares

(3,875)

(1,321)

Dividends paid

(2,259)

(2,270)

Purchase of derivative financial instruments

(250)

(531)

Repayment of term loan

14

(1,200)

(1,200)

Payment of lease liabilities

(912)

(1,135)

Cash flows from financing activities

(8,486)

(6,456)

(Decrease)/increase in cash and cash equivalents in the year

 

(13,356)

8,781

Cash and cash equivalents at the beginning of the year

 

46,512

37,189

Exchange (loss)/gain on cash

 

(326)

542

Cash and cash equivalents at the end of the year

10

32,830

46,512

*Includes transaction costs associated with the acquisition of TP Group plc.

 

Cash and cash equivalents are analysed as follows:

Note

2023£000

2022

£000

Cash and cash equivalents - Group cash

10

30,949

43,645

Cash and cash equivalents - Client registration funds

10

1,881

2,867

32,830

46,512

 

 

Extracts from notes to the financial statements

 

1. General Information

Science Group plc (the 'Company') together with its subsidiaries ('Science Group' or the 'Group') is an international science & technology consultancy and systems organisation, supported by a strong balance sheet.

 

The Group and Company Financial Statements of Science Group plc were prepared under the International Financial Reporting Standards ('IFRS') as adopted by the UK in conformity with the requirements of the Companies Act 2006 and have been audited by Grant Thornton UK LLP. Accounts are available from the Company's registered office; Harston Mill, Harston, Cambridge, CB22 7GG.

 

The Company is incorporated and domiciled in England and Wales under the Companies Act 2006 and has its primary listing on the Alternative Investment Market of the London Stock Exchange (SAG.L). The value of Science Group plc shares, as quoted on the London Stock Exchange on 31 December 2023, was 392.0 pence per share (31 December 2022: 395.0 pence per share).

 

Alternative performance measures

The Group uses alternative non-Generally Accepted Accounting Principles performance measures of 'adjusted operating profit', 'adjusted earnings per share' and 'net funds' which are not defined within IFRS. These are explained as follows:

(a) Adjusted Operating Profit

The Group calculates this measure by adjusting to exclude certain items from operating profit namely: amortisation of acquisition related intangible assets, acquisition integration costs, share-based payment charges and other specified items that meet the criteria to be adjusted.

The criteria for the adjusted items in the calculation of adjusted operating profit is operating income or expenses that are material and either arise from an irregular and significant event or the income/cost is recognised in a pattern that is unrelated to the resulting operational performance. Materiality is defined as an amount which, to a user, would influence the decision making. Acquisition integration costs include all costs incurred directly related to the restructuring, relocation and integration of acquired businesses. Adjustments for share-based payment charges occur because: once the cost has been calculated, the Directors cannot influence the share-based payment charge incurred in subsequent years; it is understood that many investors/analysts exclude the cost from their valuation analysis of the business; and the value of the share option to the employee differs considerably in value and timing from the actual cash cost to the Group.

The calculation of this measure is shown on the Consolidated Income Statement.

(b) Adjusted Earnings Per Share

The Group calculates this measure by dividing adjusted profit after tax by the weighted average number of shares in issue and the calculation of this measure is disclosed in Note 5. The tax rate applied to calculate the tax charge in this measure is the tax at the blended corporation tax rate across the various jurisdictions for the year which is 24.1% (2022: 21.4%) which results in a comparable tax charge year on year.

(c) Net Funds

The Group calculates this measure as the net of cash and cash equivalents - Group cash and Borrowings. Client registration funds are excluded from this calculation because these monies are for the purpose of payment of registration fees to regulatory bodies. This cash is separately identified for reporting purposes and is unrestricted. This measure is calculated as follows:

Note

2023

£000

2022

£000

Cash and cash equivalents - Group cash

10

30,949

43,645

Borrowings

14

(12,956)

(14,139)

Net funds

17,993

29,506

 

 

 

 

Alternative performance measures

The Directors believe that disclosing these alternative performance measures enhances shareholders' ability to evaluate and analyse the underlying financial performance of the Group. Specifically, the adjusted operating profit measure is used internally in order to assess the underlying operational performance of the Group, aid financial, operational and commercial decisions and in determining employee compensation. The adjusted EPS measure allows the shareholder to understand the underlying value generated by the Group on a per share basis. Net funds represent the Group's cash available for day-to-day operations and investments. As such, the Board considers these measures to enhance shareholders' understanding of the Group results and should be considered alongside the IFRS measures.

 

Going concern

The Directors have undertaken a comprehensive going concern review. In adopting the going concern basis for preparing these Consolidated Financial Statements, the Directors have undertaken a review of the Group's cash flows forecasts and available liquidity, along with consideration of the principal risks and uncertainties over an 18-month period to September 2025. Recognising the challenges of reliably estimating and forecasting the impact of external factors on the Group, the Directors have considered two forecasts in the assessment of going concern, along with a likelihood assessment of these forecasts being:

· Base case, which reflects the Directors' current expectations of future trading; and

· Severe but plausible downside forecast which envisages a 'stress' or 'downside' situation.

After reviewing the current liquidity position and the cash flow forecasts modelled under both the base case and stressed downside, the Directors consider that the Group has sufficient liquidity to continue in operational existence for a period of at least 18 months form the date of this report and are satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the Consolidated Financial Statements.

In reaching these conclusions the Directors noted that the Group had a cash balance at 31 December 2023 of £30.9 million (excluding client registration funds but including short- term investments) and net funds of £18.0 million, together with the undrawn Revolving Credit Facility ('RCF') of £25.0 million.

 

2. Segment Information

The Group's segmental reporting shows the performance of the operating businesses separately from the value generated by the Group's significant freehold property assets and the Corporate costs. The Consultancy Services Segment consists of three Practices: (i) Research & Development, (ii) Regulatory & Compliance and (iii) Defence & Aerospace. Financial information is provided to the Chief Operating Decision Makers ('CODMs') in line with this structure: the Consultancy Services Segment; the two Systems Businesses (Submarine Atmosphere Management and Audio Chips and Modules); the Freehold Properties and Corporate costs. 

The Consultancy Services Practices are aggregated into one Consultancy Services Segment because the Practices and the services they provide have similar economic characteristics. This aggregation does not impact the user's ability to understand the entity's performance, its prospects for future cash flows or the user's decisions about the entity as a whole as it is a fair representation of the performance of each service line.

Consultancy Services revenue includes all consultancy fees and other revenue includes recharged materials and expenses relating directly to Consultancy Services activities. Systems - Submarine Atmosphere Management revenue includes the development, manufacture and support of specialist systems for submarine atmosphere management, used in UK and International naval defence markets. Systems - Audio Chips and Modules revenue includes sales of chips and modules which are incorporated into digital radios. The Freehold Properties Segment includes the results for the two freehold properties owned by the Group. Income is derived from third party tenants from the Harston Mill site and from internal businesses which have been charged fees at an arm's length market rental rate for their utilised property space and associated costs. Corporate costs include PLC/Group costs.

The segmental analysis is reviewed to operating profit. Other resources are shared across the Group.

 

Consultancy Services

2023

£000

2022

£000

Services revenue

79,729

58,242

Other

1,553

2,423

Revenue

81,282

60,665

Adjusted operating profit

20,355

16,200

Amortisation of acquisition related intangible assets

(1,918)

(1,463)

Share-based payment charge

(1,557)

(1,249)

Operating profit

16,880

13,488

 

 

Systems - Submarine Atmosphere Management

2023

£000

2022

£000

Systems revenue - Submarine Atmosphere Management

21,265

-

Revenue

21,265

-

Adjusted operating profit

3,619

-

Amortisation of acquisition related intangible assets

(752)

-

Share-based payment charge

(77)

-

Operating profit

2,790

-

 

 

Systems - Audio Chips and Modules

2023

£000

2022

£000

Systems revenue - Audio Chips and Modules

9,975

24,979

Revenue

9,975

24,979

Adjusted operating (loss)/profit

(1,427)

3,869

Amortisation of acquisition related intangible assets

(2,274)

(2,303)

Share-based payment charge

(229)

(265)

Operating (loss)/profit

(3,930)

1,301

 

 

Freehold Properties

2023

£000

2022

£000

Inter-company property income

3,398

3,436

Third party property income

819

657

Revenue

4,217

4,093

Adjusted operating profit

597

132

Share-based payment charge

(44)

(42)

Operating profit

553

90

 

 

Corporate

2023

£000

2022

£000

Adjusted operating loss

(2,609)

(2,599)

Acquisition integration costs

(518)

(1,128)

Loss on remeasurement of equity-accounted investment

(4,762)

-

Share-based payment charge

(90)

(56)

Share of (loss)/profit of equity accounted investment

(169)

602

Operating loss

(8,148)

(3,181)

 

 

 

Group

2023

£000

2022

£000

Consultancy Services revenue

79,729

58,242

Systems revenue - Submarine Atmosphere Management

21,265

-

Systems revenue - Audio Chips and Modules

9,975

24,979

Third party property income

819

657

Other

1,553

2,423

Revenue

113,341

86,301

Adjusted operating profit

20,535

17,602

Acquisition integration costs

(518)

(1,128)

Amortisation of acquisition related intangible assets

(4,944)

(3,766)

Loss on remeasurement of equity-accounted investment

(4,762)

-

Share-based payment charge

(1,997)

(1,612)

Share of (loss)/profit of equity accounted investment

(169)

602

Operating profit

8,145

11,698

Net finance costs

(526)

(602)

Profit before income tax

7,619

11,096

Income tax charge

(2,095)

(541)

Profit for the period

5,524

10,555

 

Geographical and currency revenue analysis

 

Primary geographic markets

2023

£000

2022

£000

United Kingdom

52,522

13,240

Other European Countries

14,202

10,621

North America

29,056

35,878

Asia

16,641

26,047

Other

920

515

 

113,341

86,301

 

 

Currency

2023

£000

2022

£000

US Dollar

34,642

54,663

Euro

3,876

2,669

Sterling

74,823

28,969

113,341

86,301

 

 

 

3. Income Tax

 

The tax charge comprises:

Year ended 31 December

Note

2023

£000

2022£000

Current taxation

(3,056)

(2,666)

Current taxation - adjustment in respect of prior years

84

539

Deferred taxation

4

317

643

Deferred taxation - adjustment in respect of prior years

43

413

R&D tax credit

517

530

(2,095)

(541)

 

The adjustments in prior years are due to estimation differences related to the tax charge.

The corporation tax on Science Group's profit before tax differs from the theoretical amount that would arise using the blended corporation tax rate across the various jurisdictions applicable to profits/(losses) of the consolidated companies of 24.1% (2022: 21.4%) as follows:

2023£000

2022£000

Profit before tax

7,619

11,096

Tax calculated at domestic tax rates applicable to profits/(losses) in the respective countries

(1,836)

 

(2,374)

Expenses not deductible for tax purposes

(1,589)

(389)

Adjustment in respect of prior years - current tax

84

539

Adjustment in respect of prior years - deferred tax

43

413

Movement in deferred tax due to change in tax rate

-

(35)

Share scheme movements

554

281

Utilisation of losses previously not recognized

241

569

Tax losses not recognized

(71)

(190)

Share of (loss)/profit of equity accounted investment

(38)

115

R&D tax credit

517

530

Tax charge

(2,095)

(541)

 

The Group claims Research and Development tax credits under the R&D expenditure credit scheme. In the current year, the Group recognised a tax credit of £0.5 million (2022: £0.5 million). The Group performed a reasonable estimate of all amounts involved to determine the R&D tax credits to be recognised in the period to which it relates.

 

4. Deferred Tax

The movement in deferred tax assets and liabilities during the year by each type of temporary difference is as follows:

 

Accelerated capital allowances

£000

Tax losses

£000

Share-based payment

£000

Acquisition related intangible assets

£000

Other temporary differences

£000

Total

£000

At 1 January 2022

(46)

2,120

1,389

(2,205)

193

1,451

(Charged)/credited to the Income Statement

(131)

(190)

506

588

(130)

643

Credited to the Income Statement (adjustment in respect of prior year)

129

-

-

-

284

413

Charged to Equity

-

-

(127)

-

(414)

(541)

Effect of movements in exchange rates

76

246

-

(194)

-

128

At 31 December 2022

28

2,176

1,768

(1,811)

(67)

2,094

Credited/(charged) to the Income Statement

47

(678)

66

985

(103)

317

Deferred taxation relating to acquisitions

4

2,259

-

(5,108)

63

(2,782)

(Charged)/credited to the income statement (adjustment in respect of prior year)

(8)

-

(51)

-

102

43

(Charged)/credited to Equity

-

-

(486)

-

147

(339)

Effect of movements in exchange rates

(5)

(115)

-

85

-

(35)

At 31 December 2023

66

3,642

1,297

(5,849)

142

(702)

 

 

 

 

2023

£000

2022

£000

 

Deferred tax assets

2,071

2,176

 

Deferred tax liabilities

(2,773)

(82)

Net deferred tax (liabilities)/assets

(702)

2,094

 

 

At 31 December 2023, Science Group had £29.3 million (2022: £26.7 million) of tax losses, the largest components of which related to Frontier (£19.2 million (2022: £17.1 million)) and TP Group (£5.9 million (2022: £nil)). £9.1 million (2022: £8.7 million) of the Frontier losses, and £5.4 million (2022: £nil) of the TP Group losses are recognised as deferred tax assets which are anticipated to be used to offset future taxable profits. The balances of £10.1 million (2022: £8.4 million) of the Frontier losses and £0.5 million (2022: £nil) of the TP Group losses have not been recognised as deferred tax assets due to the uncertainty in the timing of utilisation of these losses. Aside from these amounts, the Group has other tax losses of £4.2 million (2022: £9.6 million) unrecognised as a deferred tax asset due to the low probability that these losses will be utilised.

 

5. Earnings Per Share

The calculation of earnings per share is based on the following result and weighted average number of shares:

2023

 

2022

Profit after tax

£000

Weighted average number of shares

Pence per share

Profit after tax

£000

Weighted average number of shares

Pence per share

Basic earnings per ordinary share

5,524

45,553,584

12.1

10,555

45,525,568

23.2

Effect of dilutive potential ordinary shares: share options

-

638,394

(0.1)

-

1,268,082

(0.6)

Diluted earnings per ordinary share

5,524

46,191,978

12.0

10,555

46,793,650

22.6

 

Only the share options granted are dilutive.

The calculation of adjusted earnings per share is as follows:

 

2023

2022

Adjusted* profit after tax

£000

Weighted average number of shares

Pence per share

Adjusted* profit after tax

£000

Weighted average number of shares

Pence per share

Adjusted basic earnings per ordinary share

15,187

45,553,584

33.3

13,362

45,525,568

29.4

Effect of dilutive potential ordinary shares: share options

-

638,394

(0.4)

-

1,268,082

(0.8)

Adjusted diluted earnings per ordinary share

15,187

46,191,978

32.9

13,362

46,793,650

28.6

 

*Calculation of adjusted profit after tax:

 

 

2023

£000

2022

£000

Adjusted operating profit

20,535

17,602

Finance income

679

375

Finance costs

(1,205)

(977)

Adjusted profit before tax

20,009

17,000

Tax charge at the blended corporation tax rate across the various jurisdictions 24.1% (2022: 21.4%)

(4,822)

(3,638)

Adjusted profit after tax

15,187

13,362

The tax charge is calculated using the blended corporation tax rate across the various jurisdictions in which the Group companies are incorporated.

 

 

6. Dividends

The final dividend for 2022 of £2.3 million was paid in June 2023 (2022: £2.3 million paid for 2021 in June 2022).

The Board has proposed a final dividend for 2023 of 8.0 pence per share (2022: 5.0 pence per share). The dividend is subject to approval by shareholders at the next Annual General Meeting and the expected cost of £3.6 million has not been included as a liability as at 31 December 2023.

 

7. Intangible Assets

 

 

Technical know-how and intellectual property rights

 

£000

 Customer relationships

 

 

 £000

Goodwill

 

£000

Total

 

£000

Cost

At 1 January 2022

12,306

13,915

16,585

42,806

Effect of movement in exchange rates

1,350

428

615

2,393

At 31 December 2022

13,656

14,343

17,200

45,199

Acquisitions through business combination

3,346

17,084

4,222

24,652

Effect of movement in exchange rates

(679)

(211)

(319)

(1,209)

At 31 December 2023

16,323

31,216

21,103

68,642

Accumulated amortisation

At 1 January 2022

2,464

10,391

-

12,855

Amortisation charged in year

2,172

1,594

-

3,766

Effect of movement in exchange rates

335

221

-

556

At 31 December 2022

4,971

12,206

-

17,177

Amortisation charged in year

2,349

2,595

-

4,944

Effect of movement in exchange rates

(296)

(138)

-

(434)

At 31 December 2023

7,024

14,663

-

21,687

Accumulated impairment

At 1 January, 31 December 2022 and 31 December 2023

-

7

2,225

2,232

Carrying amount

At 31 December 2022

8,685

2,130

14,975

25,790

At 31 December 2023

9,299

16,546

18,878

44,723

 

Goodwill and acquisition related intangible assets recognised arose from acquisitions during 2013, 2015, 2017, 2019, 2021 and 2023. The discount rates used for goodwill impairment reviews and the carrying amount of goodwill is allocated as follows:

 

2023

2022

Pre-tax discount rate

 

£000

Pre-tax

discount rate

£000

R&D Consultancy

17.8%

3,383

16.8%

3,383

Leatherhead Research

18.1%

650

16.9%

650

TSG Americas

17.5%

2,732

15.2%

2,874

TSG Europe

17.9%

4,546

16.6%

4,546

Frontier Smart Technologies Group

20.2%

3,345

17.5%

3,522

CMS2

16.1%

1,576

-

-

TPG Services

17.8%

2,646

-

-

 

18,878

14,975

 

Impairment review of goodwill

The Group tests goodwill annually for impairment or more frequently if there are indications that goodwill might be impaired. The recoverable amounts of the Cash Generating Units ('CGUs') are determined from value in use. (CGUs are a description of a cash-generating unit (such as a whether it is a product line, a business operation or a reportable segment as defined in IFRS8)). The key assumptions for the value in use calculations are those regarding the discount rates and growth or decline rates of revenue.

 

The Group prepares the cash flow forecasts derived from the most recent annual financial plan approved by the Board and extrapolates cash flows for the following four years based on forecast rates of growth or decline in revenue by the CGU. Beyond 5 years, cash flows were extrapolated using a terminal growth rate of 2.5% based on historic average inflation rates.

 

The Group monitors its post-tax weighted average cost of capital and those of its competitors using market data. In considering the discount rates applying to CGUs, the Directors have considered the relative sizes, risks and the inter-dependencies of its CGUs. The impairment reviews use a discount rate adjusted for pre-tax cash flows and are included in the table above.

 

 

8. Inventories

 

2023

£000

2022

£000

Raw materials

174

263

Work in progress

743

485

Finished goods

415

1,729

1,332

2,477

 

9. Trade and Other Receivables

 

2023

£000

2022

£000

Current assets:

 

Trade receivables

13,899

9,983

Provision for impairment

(100)

(207)

Trade receivables - net

13,799

9,776

Amounts recoverable on contracts

6,708

1,152

Other receivables

161

90

Other taxation and social security

768

-

VAT

222

215

Prepayments

1,657

1,759

23,315

12,992

All amounts disclosed above, except for prepayments, are receivable within 90 days.

 

 

10. Cash and Cash Equivalents

 

2023

£000

2022

£000

Cash and cash equivalents - Group cash

30,949

43,645

Cash and cash equivalents - Client registration funds

1,881

2,867

32,830

46,512

 

The Group receives cash from clients, primarily in North America, for the purpose of payment of registration fees to regulatory bodies. This cash is separately identified for reporting purposes and is unrestricted.

A balance of £10.0 million (2022: £nil) was held in two fixed term deposit accounts of £5.0 million each, with maturity dates of 31 January 2024 and 15 March 2024.

 

11. Trade and Other Payables

 

 

2023

£000

2022

£000

Current liabilities:

 

 

Contract liabilities

 

17,550

19,679

Trade payables

 

4,106

1,689

Other taxation and social security

 

1,730

1,460

VAT

 

998

250

Accruals

 

7,657

8,468

 

32,041

31,546

 

12. Provisions

 

Group

Dilapidations

£000

Restructuring

£000

Legal

£000

Other

£000

Total£000

At 1 January 2022

770

70

440

-

1,280

Provisions made during the year

44

-

190

-

234

Provisions used during the year

(2)

-

(152)

-

(154)

Provisions reversed during the year

(164)

(30)

(149)

-

(343)

Effect of movement in exchange rates

58

-

22

-

80

At 1 January 2023

706

40

351

-

1,097

Assumed in business combination

271

-

135

393

799

Disposed

-

-

-

(138)

(138)

Provisions made during the year

84

-

454

768

1,306

Provisions used during the year

(129)

(8)

(71)

-

(208)

Provisions reversed during the year

(83)

-

(289)

(34)

(406)

Effect of movement in exchange rates

(70)

-

(10)

-

(80)

At 31 December 2023

779

32

570

989

2,370

Current liabilities

387

32

570

492

1,481

Non-current liabilities

392

-

-

497

889

At 31 December 2022

706

40

351

-

1,097

Current liabilities

458

40

351

-

849

Non-current liabilities

248

-

-

-

248

 

Dilapidation provisions have been recognised at the present value of the expected obligation. These discounts will unwind to their undiscounted value over the remaining lives of the leases via a finance charge within the income statement.

The average remaining life of the leases as at 31 December 2023 is 2.7 years (2022: 1.4 years).

The restructuring provision relates to the costs associated with the closure of some non-trading Group entities.

Legal provisions reflect the best estimate of the future cost of responding to potential legal claims.

The other provision category relates to provisions made in respect of product and service deliveries that include warranty provisions. It also includes a provision for the employer's NIC liability on share options that have vested (or on the proportion that have vested). As the employee is contractually responsible for the employer's NIC on any share options exercised and is required to remit this sum to the Company prior to the share options being exercised, a corresponding asset is recognised in current assets.

13. Called-up Share Capital

 

2023

£000

2022

£000

Allotted, called-up and fully paid

 

Ordinary shares of £0.01 each

462

462

Number

Number

Allotted, called-up and fully paid

 

Ordinary shares of £0.01 each

46,185,874

46,185,874

 

The allotted, called-up and fully paid share capital of the Company as at 31 December 2023 was 46,185,874 shares (2022: 46,185,874) and the total number of ordinary shares in issue (excluding treasury shares) was 45,458,972 (2022: 45,436,823). Of the ordinary shares in issue, no shares (2022: 34,800) were held by the Frontier Smart Technologies Employee Benefit Trust. The total number of voting rights in the Company is 45,458,972 (2022: 45,402,023).

 

 

14. Borrowings

 

 

2023

£000

2022

£000

Current bank borrowings

1,200

1,200

Non-current bank borrowings

11,756

12,939

Total borrowings

12,956

 

14,139

 

 

 

2023

£000

2022

£000

Opening balance

14,139

15,323

Repayments in the year

(1,200)

(1,200)

Amortisation of loan arrangement fee

17

16

Total borrowings

12,956

14,139

 

During the year ended 31 December 2016, the Group entered into a 10-year fixed term loan of £15.0 million which is secured on the freehold properties of the Group and on which interest is payable based on SONIA plus 2.6% margin. During the year ended 31 December 2019, the Group increased this existing loan by £4.8 million to £17.5 million on similar terms. The repayment profile of the loan is £1.2 million per annum over the term with the remaining balance repaid on expiry of the loan in 2026. Costs directly associated with entering into the loan (including the loan increase), have been offset against the balance outstanding and are being amortised over the period of the loan.

During the year ended 31 December 2020, the Group drew a further £1.5 million of loan funds from the £17.5 million existing loan agreement. This was on similar terms and with no change to the loan repayment profile (i.e. the quarterly repayments remained the same and the loan balance remains payable on 30 September 2026). Costs directly associated with entering into the additional loan have been offset against the balance outstanding and are being amortised over the period of the loan.

The reconciliation of bank loans interest expense is shown below.

 

2023

£000

2022

£000

Interest expense

499

533

Interest paid

(482)

(517)

Amortisation of loan arrangement fee

(17)

(16)

Interest accrual at the year end

-

-

In December 2021 Science Group plc signed a Revolving Credit Facility ('RCF') with Lloyds Bank plc in order to provide additional capital resources to enable the execution of the Group's acquisition strategy. The RCF is for up to £25.0 million, with an additional £5.0 million accordion option. The original agreement was for a term of four years, however an option to extend the term by an additional year was taken by the Group in December 2023 (meaning the term end date is now December 2026). The margin on drawn sums is 3.3% over the Sterling Overnight Index Average ('SONIA') and is 1.1% per annum on undrawn amounts. Drawn amounts are secured on the Group's assets by debentures. The RCF is in addition to the Group's existing term loan.

The RCF has two financial covenants with which the Group needs to comply if the facility is drawn: (i) the Group's net leverage, as defined as the net debt divided by the rolling 12 month EBITDA, should not exceed 2.5; and (ii) the Group's interest cover, as defined as the rolling 12 month EBITDA divided by the rolling interest payments on all borrowings, should not be less than 4.0. Reporting is on a 6 monthly basis unless the net leverage exceeds 2, in which case reporting moves to quarterly until net leverage returns to below 2 again. For the term of the RCF, the previous covenants for the term loan are superseded by the covenants of the RCF and will not apply.

The reconciliation of RCF interest expense is shown below.

 

2023

£000

2022

£000

Interest expense

349

349

Interest paid

(268)

(268)

Amortisation of RCF arrangement fee

(81)

(81)

Interest accrual at the year end

-

-

 

In accordance with an agreed repayment schedule with the bank, bank borrowings are repayable to Lloyds Bank plc as follows:

 

2023£000

2022

£000

Within one year

1,200

1,200

Between 1 and 2 years

1,200

1,200

Between 2 and 5 years

10,600

11,800

13,000

14,200

 

In order to address interest rate risk, the Group entered into phased interest rate swaps in order to fully hedge the loan resulting in a 10-year fixed effective interest rate of 3.5%. The interest rates on the swaps range from 0.4% to 1.3% which when combined with the margin on the loan economically fix the finance cost at 3.5%. The notional amount on the interest rate swaps reduces in line with the repayment of the term loan, so an effective hedge remains throughout the term of the loan. There are 4 active swaps in place at 31 December 2023, totalling £13.0 million. Of this total, £1.8 million will mature in September 2025 and the remaining balance of £11.2 million will mature in September 2026. The fair value of the swap at 31 December 2023 was an asset of £0.9 million (2022: asset of £1.4 million).

15. Business combinations

On 26 January 2023, the Group completed the acquisition of 100% of the share capital of TP Group plc, which adds significant scale to the Group and provides a strategic entry into the defence sector. 

The acquisition of TP Group plc was an acquisition which commenced with an initial holding of 10.2% on 9 August 2021. The Group increased its shareholding with further share acquisitions across 2021 and 2022. In October 2022, the Group made an offer to acquire the remaining shares in TP Group plc through a court-approved Scheme of Arrangement. This became effective on 26 January 2023, at which point TP Group plc became a fully owned subsidiary undertaking of Science Group Plc. 

The assets and liabilities acquired were as follows:

Book Value

 

£000

Fair Value Adjustment

£000

Fair Value

 

£000

 

Assets

 

Non-current assets

 

Intangible assets

6,247

14,183

20,430

 

Goodwill

4,240

(4,240)

-

 

Property, plant & equipment

2,292

304

2,596

 

Deferred tax assets

2,469

-

2,469

 

Non-current assets classified as held for sale

2,113

-

2,113

 

17,361

10,247

27,608

 

Current assets

 

Inventories

77

-

77

 

Trade and other receivables

8,386

-

8,386

 

Current tax assets

759

-

759

 

Cash and cash equivalents

4,284

-

4,284

 

13,506

-

13,506

 

Liabilities

 

Current liabilities

 

Trade and other payables

12,412

-

12,412

 

Borrowings

5,960

-

5,960

 

Lease liabilities

354

-

354

 

18,726

-

18,726

 

Non-current liabilities

 

Provisions

661

-

661

 

Lease liabilities

2,395

(333)

2,062

 

Non-current liabilities classified as held for sale

1,325

-

1,325

 

Deferred tax liabilities

956

4,074

5,030

 

 

5,337

3,741

9,078

 

Net assets acquired

6,804

6,506

13,310

 

Goodwill (Note 7)

4,222

 

Fair value of cost of investment

17,532

 

 

£17.5 million consists of £12.4 million consideration paid in 2023 and £5.1 million fair value of the investment at the point TP Group plc became a subsidiary.

 

 

 

 

 

Consideration paid

2023£000

2022

£000

Purchase interest in subsidiary/associate

12,409

213

Debt acquired

5,960

-

Cash acquired

(4,446)

-

13,923

213

 

Non-current assets and liabilities classified as held for sale relate to the sale of the entire issued share capital of Westek Technology Ltd to Roda Computer GmbH on 29 January 2023 for a net cash consideration of £0.6 million.

On 26 January 2023, the day of the acquisition, the Group repaid the outstanding TP Group plc Revolving Credit Facility with HSBC (£6.0 million).

TP Group plc contributed £44.9 million revenue and approximately £6.2 million to the Group's profit before tax for the period between the date of acquisition and the balance sheet date, not including £1.9 million of acquired intangible asset amortisation expense. If the acquisition of TP Group plc had been completed on the first day of the financial year, the additional impact on group revenue for the period would have been £2.6 million and the additional impact on group profit would have been a reduction of £0.9 million.

The goodwill of £4.2 million is attributable mainly to the skills and technical knowledge of TP Group's workforce. A third-party expert performed a detailed review of the acquired intangible assets. The customer contracts and relationships intangible asset was valued using a multi-period excess earnings methodology. Technology and marketing intangible assets were valued using a royalty savings methodology. The deferred tax liability, in respect of the acquired intangible assets, has been calculated by using the current statutory tax rate of 25.0%.

 

16. Post balance sheet events

There are no post balance sheet events to disclose.

 

 

17. Statement by the Directors

 

Whilst the information included in this preliminary announcement has been prepared in accordance with the recognition and measurement criteria of International Financial Reporting Standards ('IFRSs') as adopted by the UK in conformity with the requirements of the Companies Act 2006, this announcement does not itself contain sufficient information to comply with IFRSs. The accounting policies adopted in this preliminary announcement are consistent with the Annual Report for the year ended 31 December 2023.

 

The financial information set out above, which was approved by the Board on 20 March 2024, is derived from the full Group accounts for the year ended 31 December 2023 and does not constitute the statutory accounts within the meaning of section 434 of the Companies Act 2006. The Group accounts on which the auditors have given an unqualified report, which does not contain a statement under section 498(2) or (3) of the Companies Act 2006 in respect of the accounts for 2023, will be delivered to the Registrar of Companies in due course.

 

The Board of Science Group approved the release of this preliminary announcement on 20 March 2024.

 

The Annual Report for the year ended 31 December 2023 will be posted to shareholders in due course and will be delivered to the Registrar of Companies following the Annual General Meeting of the Company. The report will also be available on the investor relations page of the Group's website. Further copies will be available on request and free of charge from the Company Secretary.

 

 

 

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR FLFVTVAIIFIS
Date   Source Headline
22nd Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTreasury shares issued
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTreasury shares issued & PDMR dealing
8th Apr 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSAudited results for year ended 31 December 2023
19th Mar 20247:00 amRNSNotice of Preliminary Results
26th Jan 20247:00 amRNSRule 19.6(c) confirmation of post-offer intentions
22nd Dec 20237:00 amRNSRule 19.6(b) update to post-offer intentions
18th Dec 20237:00 amRNSTransaction in Own Shares
12th Dec 20237:00 amRNSTransaction in Own Shares
5th Dec 20237:00 amRNSTransaction in Own Shares
4th Dec 20237:00 amRNSTransaction in Own Shares
30th Nov 202312:00 pmRNSTransaction in Own Shares
30th Nov 20237:00 amRNSTransaction in Own Shares
29th Nov 20237:00 amRNSTransaction in Own Shares
24th Nov 20237:00 amRNSTransaction in Own Shares
23rd Nov 20237:00 amRNSTransaction in Own Shares
22nd Nov 20237:00 amRNSTrading Update
13th Nov 20237:00 amRNSTransaction in Own Shares
10th Nov 20237:00 amRNSTransaction in Own Shares
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
6th Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 20237:00 amRNSTotal Voting Rights
30th Oct 20237:00 amRNSTransaction in Own Shares
27th Oct 20233:57 pmRNSTreasury Stock
27th Oct 20237:00 amRNSTransaction in Own Shares
26th Oct 20237:00 amRNSTransaction in own shares
25th Oct 20237:00 amRNSTransaction in Own Shares
24th Oct 20237:00 amRNSTransaction in Own Shares
23rd Oct 20237:00 amRNSTransaction in Own Shares
20th Oct 20237:00 amRNSTransaction in Own Shares
16th Oct 20237:01 amRNSTransaction in Own Shares
16th Oct 20237:00 amRNSTreasury & EBT Shares Issued
13th Oct 20237:00 amRNSTransaction in Own Shares
12th Oct 20237:00 amRNSTransaction in Own Shares
10th Oct 20237:00 amRNSTransaction in Own Shares
5th Oct 20237:00 amRNSTransaction in Own Shares
4th Oct 20237:00 amRNSTransaction in Own Shares
2nd Oct 20237:00 amRNSTransaction in Own Shares
27th Sep 20237:00 amRNSTransaction in Own Shares
26th Sep 20237:00 amRNSTransaction in Own Shares
18th Sep 20237:00 amRNSTransaction in Own Shares
13th Sep 20237:00 amRNSTransaction in Own Shares
12th Sep 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.